Jesper Heldrup
Overview
Explore the profile of Jesper Heldrup including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heldrup J, Bleyer A, Ramsey L, Schaff L, Bernhardt B, Schwartz S, et al.
Cancer Chemother Pharmacol
. 2025 Mar;
95(1):41.
PMID: 40075030
Purpose: Folinic acid (FA) rescue protocols to counter the adverse effects of high-dose methotrexate (HDMTX) vary widely, and the risk of over-rescue and potential adverse effects of excessive FA (e.g.,...
2.
Christensen S, Jensen C, Heldrup J, Taylor Z, Ramsey L, Rosthoj S
Cancer Chemother Pharmacol
. 2024 Sep;
94(6):775-785.
PMID: 39305296
Purpose: High-dose methotrexate (HDMTX) therapy is an important component in treatment regimens for acute lymphoblastic leukemia (ALL). Courses are associated with a risk of renal injury, delayed elimination, and increased...
3.
Ibarra M, Combs R, Taylor Z, Ramsey L, Mikkelsen T, Buddington R, et al.
Br J Clin Pharmacol
. 2022 Aug;
89(2):660-671.
PMID: 35998099
Aims: High-dose methotrexate (HDMTX) is an essential part of the treatment of several adult and paediatric malignancies. Despite meticulous supportive care during HDMTX administration, severe toxicities, including acute kidney injury...
4.
Ghannoum M, Roberts D, Goldfarb D, Heldrup J, Anseeuw K, Galvao T, et al.
Clin J Am Soc Nephrol
. 2022 Mar;
17(4):602-622.
PMID: 35236714
Methotrexate is used in the treatment of many malignancies, rheumatological diseases, and inflammatory bowel disease. Toxicity from use is associated with severe morbidity and mortality. Rescue treatments include intravenous hydration,...
5.
Hansson K, Orrling H, Blomgren A, Isaksson A, Schliamser G, Heldrup J, et al.
J Chromatogr B Analyt Technol Biomed Life Sci
. 2021 Nov;
1186:123007.
PMID: 34781107
High-dose methotrexate (HDMTX) is a central component in the treatment of acute lymphoblastic leukemia, osteosarcoma, and some lymphomas and brain tumors. MTX is given at lethal doses and then is...
6.
Taylor Z, Mizuno T, Punt N, Baskaran B, Navarro Sainz A, Shuman W, et al.
Clin Pharmacol Ther
. 2020 Jun;
108(3):635-643.
PMID: 32558929
Methotrexate (MTX), an antifolate, is administered at high doses to treat malignancies in children and adults. However, there is considerable interpatient variability in clearance of high-dose (HD) MTX. Patients with...
7.
Schmidt D, Kristensen K, Schroeder H, Wehner P, Rosthoj S, Heldrup J, et al.
Pediatr Blood Cancer
. 2019 Mar;
66(6):e27637.
PMID: 30835935
Background: Severely delayed elimination of methotrexate (MTX) is difficult to predict in patients treated with high-dose MTX (HD-MTX), but it may cause life-threatening toxicity. It has not been defined how...
8.
Ramsey L, Balis F, OBrien M, Schmiegelow K, Pauley J, Bleyer A, et al.
Oncologist
. 2017 Oct;
23(1):52-61.
PMID: 29079637
Implications For Practice: Glucarpidase is a rarely used medication that is less effective when given after more than 60 hours of exposure to high-dose methotrexate, so predicting early which patients...
9.
Svahn T, Mellgren K, Harila-Saari A, Asberg A, Kanerva J, Jonsson O, et al.
Pediatr Blood Cancer
. 2016 Dec;
64(7).
PMID: 27966809
Background: Carboxypeptidase G2 (CPDG ) can be used as rescue treatment in cases of delayed methotrexate elimination (DME) and Mtx-induced nephrotoxicity. Procedure: Between July 2008 and December 2014, all children...
10.
Levinsen M, Harila-Saari A, Grell K, Jonsson O, Taskinen M, Abrahamsson J, et al.
J Pediatr Hematol Oncol
. 2016 Aug;
38(8):602-609.
PMID: 27571129
We investigated efficacy and toxicity of replacing conventional triple (cytarabine, methotrexate, and hydrocortisone) intrathecal therapy (TIT) with liposomal cytarabine during maintenance therapy among 40 acute lymphoblastic leukemia patients. Twenty-eight of...